ライフサイエンスコーパス: heart transplant

1 dden cardiac death and a major indicator for heart transplant.

2 the 5-year survival benefit associated with heart transplant.

3 pensated heart failure to be evaluated for a heart transplant.

4 erging adulthood (17-24 years) in kidney and heart transplant.

5 s, 1 (3%) patient died and 4 (13%) underwent heart transplant.

6 y of nonobstructive HCM patients progress to heart transplant.

7 i-A monoclonal antibody and complement after heart transplant.

8 tation and are not observed in patients with heart transplant.

9 /year); 67% have survived, including 31 with heart transplant.

10 opathy is a key prognostic determinant after heart transplant.

11 o 13.3); 53 (8%) died and 3 (0.4%) underwent heart transplant.

12 am to manage patients with heart failure and heart transplant.

13 orbidity and mortality, frequently requiring heart transplant.

14 in preventing ischemia-reperfusion injury in heart transplant.

15 list at 113 centers, 19 815 (68%) underwent heart transplant.

16 36 received lung transplants and 8 received heart transplants.

17 rld's first series of distantly procured DCD heart transplants.

18 uding recipients of kidney, liver, lung, and heart transplants.

19 organ transplants, such as kidney, lung, and heart transplants.

20 ective application of this definition to 290 heart transplants.

21 tdischarge, 42 (38%) patients died and 2 had heart transplants.

22 h heart transplants than in patients without heart transplants.

23 s II-deficient, C57BL/6 recipients of BALB/c heart transplants.

24 nvasive testing, has been used in monitoring heart transplants.

25 years; liver transplant, 465,296 life-years; heart transplant, 269,715 life-years; lung transplant, 6

26 the study period, there were 3672 pediatric heart transplants; 3306 (90%) had a LVEF reported.

27 .8%) underwent renal transplant; 58 (17.6%), heart transplant; 54 (16.4%), lung transplant; 34 (10.3%

28 Of the 9384 candidates who did not undergo heart transplant, 5669 (60%) died (2644 while on the wai

29 Among the 454 patients who underwent heart transplant, 84 (18.5%) were ECCT.

30 istry of Transplant Recipients placed on the heart transplant active waitlist from 2004 to 2015.

31 After heart transplant, adding everolimus (EVL) to standard im

32 sted whether donor-derived MDSCs can protect heart transplant allografts in an antigen-specific manne

33 Six patients underwent heart transplant and 1 underwent heart-kidney transplant

34 Heart transplant and CABG patients had similar rates of

35 ll make the use of VADs a superior option to heart transplant and even to medical management in many

36 d, in the setting of advanced heart failure, heart transplant and left ventricular assist devices hav

37 ned by the difference between survival after heart transplant and waiting list survival without trans

38 of death, left ventricular assist device, or heart transplant, and (2) degree of echocardiographic le

39 l, 10 patients (6%) died, 14 (9%) received a heart transplant, and 32 (20%) had malignant ventricular

40 No association was present for heart transplant, and lung transplant was associated wit

41 Adults receiving their first heart transplant, and not on dialysis, were included in

42 verter-defibrillator discharges, 2 underwent heart transplants, and 2 were resuscitated after cardiac

43 ng the search terms "cardiac transplant" or "heart transplant," and "statin" for a literature search.

44 ary treatment strategies, including ICDs and heart transplant, are associated with significantly lowe

45 The survival benefit associated with heart transplant as defined by the difference between su

46 lmonary exercise testing from 87 consecutive heart transplant assessment patients and 18 healthy cont

47 ned from 822 consecutive patients undergoing heart transplant at Columbia University Medical Center b

48 efly luciferase protein in a series of three heart transplants at a five-day post-transplant endpoint

49 ged 18 to 64 receiving first-time orthotopic heart transplants between July 2006 and December 2013 we

50 enhances both acute and chronic rejection of heart transplants, but it is unclear how this inflammati

51 can contribute significantly to rejection of heart transplants by activation of complement and intera

52 y-mediated rejection and a highly sensitized heart transplant candidate, we also observed a significa

53 LVAD explanted (recovered patients), and 24 heart transplant candidates (HTx)-and 97 healthy control

54 ement of the increasing number of sensitized heart transplant candidates has become a recurrent issue

55 ned relatively stable, whereas the number of heart transplant candidates has risen.

56 This study identified 28,548 heart transplant candidates in the Organ Procurement and

57 rgency, the US heart allocation system ranks heart transplant candidates largely according to the sup

58 dded cardiogenic shock requirements for some heart transplant candidates listed with specific types o

59 nge in policies related to the management of heart transplant candidates presenting with INTERMACS pr

60 e analyzed mortality and morbidity in 33,073 heart transplant candidates registered on the United Net

61 The number of adult heart transplant candidates waiting at the most urgent s

62 ty panel reactive antibody [CDC PRA+], C1q+) heart transplant candidates were treated with the combin

63 43/160) and 21% (n = 11/53) in the lung and heart transplant candidates, respectively.

64 In this registry-based study of US heart transplant candidates, transplant center was assoc

65 scopic complication occurred in the lung and heart transplant candidates.

66 improves waiting list survival for pediatric heart transplant candidates.

67 Eligible heart-transplant candidates (aged >18 years) were random

68 for patients with advanced HF referred to a heart transplant center.

69 en October 2012 and October 2015 in the 6 UK heart transplant centers Preoperative donor and recipien

70 tre, randomised non-inferiority trial at ten heart-transplant centres in the USA and Europe.

71 There is no consensus within the heart transplant community about whether patients who us

72 h nondilated cardiomyopathy (CMP) listed for heart transplant compared with children with dilated CMP

73 death (n=12), progressive heart failure and heart transplant complications (n=5), or postoperatively

74 ients with AAD were compared with matched 30 heart transplant controls.

75 The The SCandinavian HEart transplant De-novo stUdy with earLy calcineurin in

76 SCandinavian HEart transplant De-novo stUdy with earLy calcineurin in

77 primary end point of all-cause mortality or heart transplant (death/transplant) during a median foll

78 ation in VSMCs isolated from 151 multiethnic heart transplant donors.

79 we compared trends in the utilization rates (hearts transplanted/donors recovered) of HCV-uninfected

80 literature had severe disease with death or heart transplant during the first year of life.

81 jor limitations with only approximately 2500 hearts transplanted each year.

82 A total of 240 heart transplant endomyocardial biopsies were assessed.

83 participants was selected to represent post-heart-transplant events, with and without acute rejectio

84 oup of patients included in the Scandinavian Heart Transplant Everolimus De Novo Study With Early Cal

85 many, including implantable defibrillators, heart transplant, external defibrillation/therapeutic hy

86 that previously revealed ABMR in kidney and heart transplants failed to reveal a liver ABMR phenotyp

87 Accurate risk stratification of early heart transplant failure is required to avoid futile tra

88 ed out-of-hospital cardiac arrest (n=20), or heart transplant for advanced heart failure (n=12), 1.8%

89 ers, high survival benefit centers performed heart transplant for patients with lower estimated expec

90 nefit significantly above the mean performed heart transplant for recipients who had significantly lo

91 udy aimed to evaluate the impact of CRT upon heart transplant-free survival in pediatric and congenit

92 ssynchrony, CRT was associated with improved heart transplant-free survival.

93 All children </=21 years of age listed for heart transplant from 2011 to 2015 who received a TCS de

94 Of 4565 pediatric primary heart transplants from 1994 to 2013, 3741 had complete d

95 Single-organ first-time adult heart transplants from 2003 to 2017 were evaluated from

96 he authors report their experience of 23 DCD heart transplants from 45 DCD donor referrals since 2014

97 database was queried for isolated pediatric heart transplants from January 1, 1994, to December 31,

98 rospective study was performed for pediatric heart transplants from the United Network of Organ Shari

99 easured in sera of mice grafted with skin or heart transplants from various donor strains and in sera

100 nt group compared to 32% (n = 79/245) in the heart transplant group and 27% (n = 43/160) and 21% (n =

101 Heart transplant has been accepted as the standard treat

102 In hypertrophic cardiomyopathy (HCM), heart transplant has been predominantly confined to pati

103 Several areas of pediatric heart transplant have had significant developments over

104 rdial coronary artery disease, patients with heart transplants have lower MPRI than patients without

105 not kidney (HR, 0.96; 95% CI, 0.92-1.01) or heart transplant (HR, 1.02; 95% CI, 0.93-1.10).

106 The sickest children among those listed for heart transplant (HT) are also at higher risk of post-tr

107 ter differences in short-term survival after heart transplant (HT) are known.

108 Risk factors for early mortality after heart transplant (HT) have not been used for quantitativ

109 exercise testing is a class I indication for heart transplant (HT) listing in children.

110 mong those with heart failure, and poor post heart transplant (HT) outcomes.

111 e use of hemodynamic assessment in pediatric heart transplant (HT) patients, expected intracardiac pr

112 and cardiovascular deconditioning that place heart transplant (HT) recipients at increased cardiovasc

113 We compared risk stratification of heart transplant (HT) recipients for early post-HT morta

114 We report 2 cases of heart transplant (HT) recipients with COVID-19.

115 onary artery vasculopathy (CAV) in pediatric heart transplant (HT) recipients.

116 Despite low risk of late rejection after heart transplant (HT), surveillance endomyocardial biops

117 ) is the major cause of late mortality after heart transplant (HT), there is a need to identify marke

118 the functional status (FS) of children after heart transplant (HT).

119 dysfunction is a common finding early after heart transplant (HT).

120 From 2004 to 2009, we identified 24 isolated heart transplant (HTx) and 10 H+LTx recipients in whom t

121 Data on the prevention of fractures after heart transplant (HTx) are controversial in the literatu

122 nded clinical trial in nonsensitized primary heart transplant (HTX) recipients.

123 -hospital mortality after cholecystectomy in heart transplant (HTx) recipients.

124 roducing Enterobacteriaceae was performed in heart transplant (HTx), lung transplant (LTx), and mecha

125 By using a nondiabetic mellitus (non-DM) heart transplanted (HTX) in diabetes mellitus (DM) recip

126 r-old white man with a history of orthotopic heart transplant, immunosuppressed with low-dose cyclosp

127 apidly progressive cardiomyopathy, requiring heart transplant in 4.

128 tors of long-term all-cause mortality and/or heart transplant in CRT patients.

129 n their use, which now exceeds the volume of heart transplants in the United States, with the greates

130 ts (2.2%) either received or were listed for heart transplant, including 20 with normal systolic func

131 The number of adult heart transplants increased from 2954 pre- to 3032 posti

132 Our findings show that risk of ESRD post-heart transplant increases with worsening eGFR at waitli

133 ty and an elevated risk of acute and chronic heart transplant injury in humans.

134 AAD after heart transplant is a heterogeneous process characterize

135 Elevated serum creatinine at the time of heart transplant is an independent predictor of posttran

136 Conclusion: ALC measured at one month post-heart transplant is associated with an increased risk of

137 Heart transplant is indicated when conservative surgery

138 nce of preserved systolic function, for whom heart transplant is the sole definitive therapeutic opti

139 center reports and with data from kidney and heart transplants (KTX and HTX).

140 dolent immune injury of the vasculature of a heart transplant limits long-term graft and recipient su

141 ational study of 29 199 adult candidates for heart transplant listed on the national transplant regis

142 Act (ACA) has been associated with increased heart transplant listings among blacks, who are dispropo

143 Four thousand four hundred seventy-one heart transplants met the study inclusion criteria.

144 In a heart transplant model we showed that macrophage-specifi

145 Here, using a murine heart transplant model, we determined that only a small

146 Using an in vivo murine heart transplant model, we show that preserving donor he

147 ations, using murine MHC-mismatched skin and heart transplant models, donor-derived drug-modified DCs

148 Fontan 1, 54 subjects (10%) have received a heart transplant (n = 23) or died without transplantatio

149 Heart transplant (n=43) and CABG patients were referred

150 Low rates of heart transplant now require longer periods of left vent

151 for Organ Sharing) database was queried for heart transplants occurring between October 31, 1987, an

152 study evaluated whether minority orthotopic heart transplant (OHT) recipients tend to be transplante

153 was associated with markedly reduced risk of heart transplant or death (hazard ratio, 0.24 [95% CI, 0

154 Heart transplant or death occurred in 12 (19%) PSM-CRT s

155 nitiation of mechanical circulatory support, heart transplant, or death.

156 ble left ventricular assist device (LVAD) or heart transplant, or experience myocardial recovery.

157 line characteristics and incident mortality, heart transplant, or nonelective cardiovascular hospital

158 al free from a composite end point of death, heart transplant, or placement of left ventricular assis

159 strongest relative association measure for a heart transplant outcome with a risk factor was 8.6 (rec

160 DCD heart transplant outcomes are excellent.

161 ith body mass index >=40 (severe obesity) on heart transplant outcomes.

162 etails vismodegib use in an immunosuppressed heart transplant patient receiving cyclosporine therapy.

163 Pediatric heart transplant patients (n=106) bridged to transplanta

164 h EMB for rejection surveillance in selected heart transplant patients and does not result in increas

165 Heart transplant patients are followed with periodic rig

166 atheterization data from clinical records of heart transplant patients are used to identify patient-s

167 Sixty heart transplant patients meeting inclusion criteria wer

168 splant with EXCOR versus status 1A pediatric heart transplant patients not transplanted with ventricu

169 These results suggest that de novo heart transplant patients randomized to everolimus and l

170 Seventy-seven heart transplant patients underwent 118 subsequent anest

171 nt ischemia is likely to occur frequently in heart transplant patients with denervated hearts and cor

172 ctively compared 20 consecutive asymptomatic heart transplant patients without suspicion of microvasc

173 h is used to describe cardiac function in 10 heart transplant patients, five of which had multiple ri

174 antiviral therapy appears effective in D+/R- heart transplant patients, whereas in lung transplantati

175 odies in an international study of pediatric heart transplant patients.

176 ography were predictors of adverse events in heart transplant patients.

177 cardiac MRI was positive for ischemia in two heart transplant patients; these findings were confirmed

178 In the 3-year registry cohort of heart transplanted patients, those who received quadrith

179 However, a level of 10 to 12 heart transplants per year corresponds to the upper limi

180 ears old) recipients of a primary orthotopic heart transplant performed between 2000 and 2012 were in

181 onsecutive first recipients of a noncombined heart transplant performed between 2009 and 2015 at our

182 ase, we selected all first noncombined adult heart transplants performed between 2014 and 2017 for va

183 to conduct a retrospective analysis of adult heart transplants performed in the United States between

184 ng cytomegalovirus infections in maintenance heart transplant populations.

185 ice insertion (heart failure samples) and at heart transplant (post-left ventricular assist device sa

186 pective analysis of patients followed in the heart transplant program at Barnes Jewish Hospital from

187 early disseminated fungal infections in our heart transplant program, a retrospective analysis was c

188 establishing and directing the first Swedish heart transplant program.

189 M-AHEAD (Diabetes and Lipid Accumulation and Heart Transplant) prospective ongoing study (NCT03546062

190 ey sent electronically to 1643 United States heart transplant providers between June and August 2019.

191 A total of 360 heart transplant providers responded from 26 countries.

192 diac mortality rate was 0.8%, and annualized heart transplant rate was 0.9%.

193 vasculopathy (CAV) is a major contributor of heart transplant recipient mortality.

194 recipients, 1 liver transplant recipient, 1 heart transplant recipient, and 1 lung transplant recipi

195 ting factor in the long-term survival of the heart transplant recipient.

196 In nonrejecting, otherwise healthy heart transplant recipients (>1 year after surgery, n=10

197 The study cohort comprised 34 198 heart transplant recipients (76.3% men, 23.7% women) bet

198 One hundred and fifty-two heart transplant recipients (age, 54+/-15 years; 29% wom

199 tis jirovecii pneumonia (PCP) occurred among heart transplant recipients (HTR) at the outpatient clin

200 Heart transplant recipients (n = 138) scheduled for rout

201 prospective clinical study including healthy heart transplant recipients 6 months to 25 years of age

202 Systemic hypertension is prevalent in heart transplant recipients and has been partially attri

203 ith invasive angiography in detecting CAV in heart transplant recipients and may be a preferable scre

204 he development of therapeutic strategies for heart transplant recipients and patients, who are vulner

205 culating antibodies, presents challenges for heart transplant recipients and physicians.

206 A similar pattern was observed in heart transplant recipients at both elevated and standar

207 hed (female donor heart to a male recipient) heart transplant recipients by a combination of chromoge

208 accurately diagnose acute rejection (AR) in heart transplant recipients could obviate the need for s

209 this study conducted a serial study of human heart transplant recipients evaluating cardiac effects o

210 We retrospectively reviewed 329 heart transplant recipients followed up at our instituti

211 Serum samples were taken from pediatric heart transplant recipients for markers of inflammation

212 r SED is associated with shorter survival in heart transplant recipients in England and should be con

213 We identified 10 943 adult (>/=18 years) heart transplant recipients in the United Network of Org

214 Whether myocardial fibrosis in heart transplant recipients is independently associated

215 is home blood pressure monitoring (HBPM) in heart transplant recipients is not known.

216 aimed to test the hypothesis that pediatric heart transplant recipients of grafts with depressed ven

217 In the randomized SCHEDULE trial, de novo heart transplant recipients received (1) everolimus with

218 We prospectively monitored 617 heart transplant recipients referred from 4 French trans

219 Using a cohort of consecutive heart transplant recipients that had cardiovascular magn

220 ssed a single-center cohort of 64 orthotopic heart transplant recipients transplanted between 1994 an

221 er retrospective cohort study examined adult heart transplant recipients transplanted between 2000 an

222 diac myosin (CM)-specific immunity on murine heart transplant recipients treated with donor-specific

223 ndomized studies, which compared outcomes in heart transplant recipients undergoing statin therapy to

224 cardiovascular magnetic resonance imaging in heart transplant recipients was independently associated

225 Heart transplant recipients were from 4 academic centers

226 When male and female heart transplant recipients were matched for recipient a

227 n an open-label, 24-month trial, 721 de novo heart transplant recipients were randomized to everolimu

228 scores have primarily been used to identify heart transplant recipients who have a low probability o

229 Heart transplant recipients with >=2 known risk factors

230 r block in healthy pediatric and young adult heart transplant recipients with minimal risk when low i

231 ctic strategy achieved favorable outcomes in heart transplant recipients with pfDSA.

232 However, in pediatric heart transplant recipients with PRA greater than 50% or

233 e first preliminary study demonstrating that heart transplant recipients with preformed class II DSA

234 Furthermore, infection of rat heart transplant recipients with RCMV containing the r12

235 Among heart transplant recipients, 5389 (27%) died or underwen

236 cipients, 102 lung transplant recipients, 79 heart transplant recipients, and 15 recipients of other

237 to study early withdrawal of CNIs in de novo heart transplant recipients, comparing an everolimus-bas

238 with reduced cyclosporine dosing in de novo heart transplant recipients, in particular with everolim

239 In heart transplant recipients, myocardial fibrosis is seen

240 on as seen long-term after "A-into-O" infant heart transplant recipients, normal anti-A antibody prod

241 In 105 heart transplant recipients, serial (baseline and 1-year

242 lel-group, open-label trial in de novo adult heart transplant recipients, undertaken at transplant ce

243 and highly phenotyped prospective cohort of heart transplant recipients, we identified 4 CAV traject

244 ative right heart failure (RHF) in pediatric heart transplant recipients.

245 acardially and are, thus, maintained even in heart transplant recipients.

246 is suggests that statins improve survival in heart transplant recipients.

247 pathy (CAV) limits the lifespan of pediatric heart transplant recipients.

248 ancy is a major cause of death in orthotopic heart transplant recipients.

249 ves a reliable estimate of BP burden in most heart transplant recipients.

250 AD) is an important cause of morbidity among heart transplant recipients.

251 r HBPM adequately identifies hypertension in heart transplant recipients.

252 continues to limit the long-term survival of heart transplant recipients.

253 BPM is useful for the long-term follow-up of heart transplant recipients.

254 ostic marker for post-transplant survival in heart transplant recipients.

255 concentration on post-transplant outcome in heart transplant recipients.

256 igen bead assay before transplantation in 51 heart transplant recipients.

257 ntimal proliferation at 12 months in de novo heart transplant recipients.

258 fits and costs for BTT-VAD versus nonbridged heart transplant recipients.

259 dialysis treatment on subsequent survival in heart transplant recipients.

260 The majority occurred as late PTLD in male heart transplant recipients.

261 emerging as a strong predictor of outcome in heart transplant recipients.

262 etter prognosis of female compared with male heart transplant recipients.

263 ant populations, it has not been assessed in heart transplant recipients.

264 ses predominated (51%) in kidney, liver, and heart transplant recipients.

265 ting risk scores on a contemporary cohort of heart transplant recipients.

266 a well-described histopathologic feature in heart transplant recipients.

267 Currently, women represent <25% of heart transplant recipients.

268 at an increased cost relative to nonbridged heart transplant recipients: $100 841more in costs and 1

269 ecipients, 10 liver-transplant recipients, 5 heart-transplant recipients, 5 kidney and pancreas-trans

270 By means of the Spanish National Heart Transplant Registry database, we identified 704 ad

271 n is upregulated in patients with kidney and heart transplant rejection and may account for perpetuat

272 Nanoparticle macrophage PET-CT detects heart transplant rejection and predicts organ survival b

273 pact the strength, phenotype, or kinetics of heart transplant rejection in mice and (b) does not impa

274 s of gene transcripts to refine diagnosis of heart transplant rejection.

275 All-cause death or heart transplant served as a combined primary end point.

276 between available animal models and clinical heart transplant settings that are potentially hindering

277 patients (<18 years old) from the Pediatric Heart Transplant Study (PHTS) database listed for heart

278 Patients enrolled in the Pediatric Heart Transplant Study (PHTS) from 1996 to 2006 were str

279 This study reviewed Pediatric Heart Transplant Study data from 1993 to 2009.

280 ysiological perturbations that can influence heart transplant success and recipient survival.

281 neral reporting of important determinants of heart transplant success was mixed, and assessment of po

282 h EXCOR is comparable with overall pediatric heart transplant survival and superior to survival after

283 f myeloid cells required for prolongation of heart transplant survival induced by costimulatory block

284 study sought to determine whether bridge-to-heart transplant survival with a TCS device is superior

285 Allogeneic heart transplants survived for 86.25+/-13.8, 46.3+/-4.6,

286 adenoson is less pronounced in patients with heart transplants than in patients without heart transpl

287 One patient had an orthotopic heart transplant, the second had a deceased donor kidney

288 story of Kawasaki disease (KD) and pediatric heart transplant (TX) recipients.

289 Patients with a history of heart transplant undergoing dipyridamole rubidium-82 pos

290 ts of MHC class II-mismatched B6.C-H-2(bm12) heart transplants versus wild-type (WT) recipients.

291 Heart transplant volumes are not matching growing demand

292 Mortality and morbidity on the heart transplant waiting list have decreased.

293 number of new active adult candidates on the heart transplant waiting list increased by 19.2%.

294 rted and medically managed candidates on the heart transplant waiting list.

295 In 2011, the rate of pediatric heart transplants was 124.6 per 100 patient-years on the

296 nce among patients receiving publicly funded heart transplants was associated with improved outcomes.

297 ber 2009, adult patients undergoing isolated heart transplant were prospectively classified as ECCT b

298 In this dataset, 12 363 adult de novo heart transplants were performed, and the median DSN was

299 17% to 51%) among those who did not undergo heart transplant, which is a survival benefit of 44% (IQ

300 22 SOT recipients (13 renal and 8 lung and 1 heart transplants) with recurrent or ganciclovir-resista